MAP Congress 2018: Interpreting Molecular Alterations for Clinical Practice

LUGANO, Switzerland – The Molecular Analysis for Personalised therapy (MAP) Congress is a one-of-a-kind meeting designed to answer the critical question about how to integrate in daily practice the wealth of information coming from the analysis of tumour samples.

MAP 2018 will be held in Paris, France, 14-15 September 2018 and it is a joint initiative of  Cancer Research UK (CRUK), Unicancer and the European Society for Medical Oncology (ESMO). With a high-level programme developed by a faculty of highly influential key opinion leaders, the MAP Congress will provide oncologists with expert guidance on interpreting genomic alterations to design tailored treatment for their patients.

Key themes and programme highlights

  • From “traditional” precision medicine to the use of applied maths, to precision immuno-oncology, to the impact of infectious diseases
  • Microsatellite instability and immunotherapeutics
  • From therapeutic targets to innovative clinical trials
  • Understanding the clonal evolution of cancer

Full programme can be found online and abstract related sessions details will be added nearer the time.

Also, keep an eye on the Keynote lectures: 

  • Emergent and emerging kinase targets – Pater Parker, UK – 14 September 2018 at 16:20
  • Variant detection for precision medicine - Núria López-Bigas, ES – 15 September 2018 at 10:00
  • Clonal hematopoiesis - Markus Manz, DE - 15 September 2018 at 14:00

Media registration

To receive press accreditation, media representatives are required to observe and abide by the media policy.
To register for the event, please fill out the  complimentary media registration form. Media registration in advance is strongly recommended.

We look forward to welcoming you in Paris.

For further information please contact:
MAP Press Office - media@esmo.org

Notes to Editors

Please make sure to use the official name of the meeting in your reports: MAP Congress

Official Congress hashtag: #MAP2018

About the European Society for Medical Oncology (ESMO)

ESMO is the leading professional organisation for medical oncology. With 18,000 members representing oncology professionals from over 150 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.
ESMO’s educational resources support an integrated, multi-professional approach to cancer care. We have European roots and a global reach: we welcome oncology professionals from around the world and we seek to erase boundaries in cancer care as we pursue our mission across oncology, worldwide.  

About Cancer Research UK (CRUK)

Cancer Research UK (CRUK) is the largest independent funder of cancer research in the world. Every year CRUK invest around £350 million in world-leading research and innovative ideas that they believe will have the greatest impact for the public and cancer patients. CRUK’s vision is to bring forward the day when all cancers are cured by supporting excellent research as well as influencing policy, providing information and empowering the public to ensure that the outputs of research are adopted. This work is almost entirely funded through the generosity of the public. CRUK partner with a range of organisations, ensuring that cancer is tackled on a global stage.

About Unicancer

Unicancer, a major French player in oncology, groups together the 18 French Comprehensive Cancer Centers (FCCCs), at 20 hospital sites throughout France. They are private, non-profit health establishments exclusively dedicated to care, research and education in cancer.
Unicancer’s R&D is the driving force of Unicancer’s research and, as an academic sponsor, it works directly with the research units of the FCCCs and other health establishments (university hospitals, public hospitals and private clinics) in France and abroad. The mission of the direction of research and development is to implement Unicancer’s global research strategy. The primary objective of Unicancer’s R&D is to help increase knowledge about cancer for the rapid transfer of innovations to the patient’s bedside and continuous improvement of patient care.